Adjuvant Therapy of Lung Cancer: New Perspectives

Overview

This one-hour webinar will:

  • Give an in-depth overview of  the state-of-the-art of adjuvant therapy of resected early-stage non-small cell lung cancer (NSCLC).
  • Appraise the respective roles of radiation therapy and systemic therapy.
  • Identify major clinical trials likely to impact patient care.
  • Discuss the emerging status of immunotherapy and its incorporation in adjuvant protocols.
  • Provide an update on the utilization of molecular drivers to guide treatment.
Date
Jun 20, 2017 -
Jun 20, 2017
Location

Online

 After viewing this program, attendees will:

  • Assess treatment options, including adjuvant systemic  therapy and/or radiation therapy for patients with early-stage NSCLC.
  • Evaluate patients for inclusion in clinical trials utilizing new agents and new approaches to adjuvant therapy.
  • Understand the current role of immunotherapy in adjuvant therapy protocols.
  • Discuss the implications of recent data from adjuvant therapy clinical trials reported at the recent 2017 annual meeting of the American Society of Clinical Oncology Meeting (ASCO).

Giorgio V. Scagliotti, MD
University of Torino, Professor of Medical Oncology, Department of Oncology.

Paul Van Houtte, MD
Professor, Institut Jules Bordet Universite, Libre Bruxelles, Belgium.

For any inquiries, please contact meetings@iaslc.org.

 After viewing this program, attendees will:

  • Assess treatment options, including adjuvant systemic  therapy and/or radiation therapy for patients with early-stage NSCLC.
  • Evaluate patients for inclusion in clinical trials utilizing new agents and new approaches to adjuvant therapy.
  • Understand the current role of immunotherapy in adjuvant therapy protocols.
  • Discuss the implications of recent data from adjuvant therapy clinical trials reported at the recent 2017 annual meeting of the American Society of Clinical Oncology Meeting (ASCO).

Giorgio V. Scagliotti, MD
University of Torino, Professor of Medical Oncology, Department of Oncology.

Paul Van Houtte, MD
Professor, Institut Jules Bordet Universite, Libre Bruxelles, Belgium.

For any inquiries, please contact meetings@iaslc.org.

Share